Key Business Transactions

1. Financial Results Approval

The Board considered and approved the unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The statutory auditors, M/s. SSJNB & Co, issued a limited review report with an unmodified opinion.

Standalone Financial Results (₹ in Lakhs):

  • Revenue from operations: ₹8,842.73 (Q1 FY27) vs ₹6,563.51 (Q1 FY26)
  • Total Income: ₹8,888.44 (Q1 FY27) vs ₹6,637.62 (Q1 FY26)
  • Profit before tax: ₹116.10 (Q1 FY27) vs ₹32.31 (Q1 FY26)
  • Net profit: ₹116.10 (Q1 FY27) vs ₹32.31 (Q1 FY26)
  • Basic EPS: ₹0.73 (Q1 FY27) vs ₹0.20 (Q1 FY26)
  • Paid-up equity share capital: ₹1,592.09 lakhs (face value ₹10 per share)

Consolidated Financial Results (₹ in Lakhs):

  • Revenue from operations: ₹8,861.61 (Q1 FY27) vs ₹6,587.09 (Q1 FY26)
  • Total Income: ₹8,905.43 (Q1 FY27) vs ₹6,659.31 (Q1 FY26)
  • Profit before tax: ₹113.77 (Q1 FY27) vs ₹20.85 (Q1 FY26)
  • Net profit: ₹113.77 (Q1 FY27) vs ₹20.85 (Q1 FY26)
  • Profit attributable to equity holders: ₹112.35 (Q1 FY27) vs ₹20.06 (Q1 FY26)
  • Basic EPS: ₹0.71 (Q1 FY27) vs ₹0.13 (Q1 FY26)

2. Director Designation Changes

  • Mr. Ravindra Kumar Kothari (DIN: 03418320): Change from Non-Executive Director to Whole-Time Director (Executive Director) effective October 1, 2026, subject to shareholder approval at ensuing AGM.
  • Mr. Virupakshaya Himesh (DIN: 08554422): Change from Whole-Time Director to Non-Executive Director effective October 1, 2026, subject to shareholder approval at ensuing AGM.

3. Joint Venture Investment

Approved investment of up to ₹9 crore in a proposed Joint Venture entity to be incorporated in the Republic of the Philippines. The investment is within the Board's approval powers under Section 186 of the Companies Act, 2013 and subject to compliance with FEMA, Overseas Investment framework, and other applicable laws.

JV Details:

  • Partners: Bal Pharma Limited (65% stake) and Hemera International Private Limited, Singapore (35% stake)
  • Business: Registration, importation, commercialization, distribution and sale of designated pharmaceutical products in Philippines
  • Strategic objective: Market penetration in Philippines with option for expansion into other ASEAN markets
  • Consideration: Equity investment & funding via bank transfer
  • Not a related party transaction

4. Warrant Allotment

Approved allotment of 10,00,000 warrants to Mr. Shailesh Siroya, Promoter of the Company, on preferential basis at issue price of ₹84 per warrant, aggregating ₹8,40,00,000. This follows shareholder approval obtained through Postal Ballot on August 8, 2026.

Warrant Terms:

  • 25% of issue price (₹2,10,00,000) already received
  • Each warrant convertible into one fully paid-up equity share (face value ₹10) upon payment of balance 75% within 18 months from allotment date
  • Conversion subject to SEBI (ICDR) Regulations, 2018 and other applicable laws

Subsidiaries Included in Consolidation

  • Lifezen Health Care Private Limited
  • Balance Clinics LLP
  • Bal Research Foundation
  • Aurum Research & Analytical Solutions Private Limited